Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2022-03-21 Audit Report / Informat…
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Daewoong Co., Ltd. for the fiscal year 2021. It includes the independent auditor's report, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and notes. While it contains financial statements, it is explicitly titled as an audit report and includes the auditor's opinion, which aligns with the 'Audit Report / Information' (AR) category rather than a full 10-K annual report, as it focuses on the audit process and results. FY 2021
2022-03-21 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding the voluntary discontinuation of a Phase 2/3 clinical trial for a COVID-19 treatment (DWJ1248). It is a formal disclosure of a material management event (major management matter) filed with the Korea Exchange (KRX). Since it details a specific regulatory/clinical development update that does not fit into financial reporting or specific corporate actions like dividends or share buybacks, it is classified as a Regulatory Filing (RNS).
2022-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Daewoong Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's business report, including financial statements and governance information. This type of document is standard for providing shareholders with the necessary information to vote at an AGM, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement) used to request shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting, the agenda, and proxy voting procedures. While it includes financial statements as part of the disclosure, the primary purpose of the document is the solicitation of proxies for the AGM, making it a Proxy Solicitation & Information Statement.
2022-03-14 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific number of shares disposed of, the dates of disposal, the purpose (stock option exercise), and the resulting change in treasury share holdings. This falls under the category of a company reporting the disposal or transaction of its own shares.
2022-03-11 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Daewoong titled 'Submission of Audit Report' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, revenue, profit), and auditor information for the fiscal year ending 2021. It is a short, structured announcement (under 5,000 characters) that serves as a formal notification of the audit report's completion and submission to the regulatory body (KRX). According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the full audit report itself. FY 2021
2022-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.